PSNL
Personalis Inc

2,677
Mkt Cap
$838M
Volume
956,730.00
52W High
$10.95
52W Low
$2.83
PE Ratio
-7.43
PSNL Fundamentals
Price
$9.45
Prev Close
$8.93
Open
$8.86
50D MA
$6.42
Beta
2.21
Avg. Volume
887,312.48
EPS (Annual)
-$1.37
P/B
4.39
Rev/Employee
$369,493.45
Loading...
Loading...
News
all
press releases
Personalis to Announce Third Quarter 2025 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·7d ago
News Placeholder
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate...
Business Wire·8d ago
News Placeholder
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Tempus AI's PurIST test secures clinical validation, helping personalize treatment choices for advanced pancreatic cancer patients.
Zacks·1mo ago
News Placeholder
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·2mo ago
News Placeholder
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·4mo ago
News Placeholder
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
chainwire·6mo ago
News Placeholder
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen's 45th Annual Health Care Conference on...
Business Wire·8mo ago

Latest PSNL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.